While guidelines support metformin as a therapeutic option for diabetic patients with mild-to-moderate renal insufficiency, the frequency and outcomes of metformin use in kidney transplant recipients are not well described. We integrated national U.S. transplant registry data with records from a large pharmaceutical claims clearinghouse (2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015). Associations (adjusted hazard ratio, 95% LCL aHR 95% UCL ) of dia- 
inhibitors. Thiazolinediones are usually avoided due to concerns about edema and bone loss. 16 Although recent data suggest renal benefit associated with sodium-glucose cotransporter 2 (SGLT-2) inhibitors in the general diabetic population with high cardiovascular risk 17 and those with early chronic kidney disease (CKD), 18 there are minimal data on their use in the transplant population.
The concern of lactic acidosis in patients with low GFR prompts many clinicians to avoid prescribing metformin in transplant recipients. This is despite recent data supporting the safety and efficacy of metformin use in nontransplant patients with mildto-moderate CKD. 19 However, some experts caution against the use of metformin after kidney transplant due to heightened concerns of lactic acidosis as well as the relative inefficiency of metformin alone to provide adequate glycemic control exacerbated by immunosuppression. 20 On the other hand, metformin has been proposed as a strategy to prevent NODAT by reducing beta-cell stress posttransplant. 21 Thus, the potential risks and outcomes associated with metformin in kidney transplant recipients remain controversial.
To advance the understanding of the patterns of use, safety, and outcomes associated with metformin treatment in kidney transplant recipients with pretransplant type 2 diabetes mellitus, we examined a linkage of national transplant registry data with medication fill records from a large pharmaceutical claims clearinghouse. We examined the correlates of metformin use in the first year after transplant and associations with graft and patient outcomes over the subsequent year.
| ME THODS

| Data sources
National registry data for this study were obtained from the SRTR. 22 The SRTR registry contains data on all transplant candidates, recipients, and donors in the United States (U.S.), provided by the Organ Procurement and Transplantation Network (OPTN). 21 The Health Pharmacy fill data were assembled by linking SRTR records for kidney transplant recipients with billing claims from Symphony Health Solutions (SHS), a large U.S. pharmaceutical claims data warehouse that maintains prescription drug fill records including self-paid fills and those reimbursed by private and public payers. 
SHS comprises National Council for Prescription
| Sampling and exposure definitions
Patients selected for analysis had SRTR records of kidney-alone 
| Acute rejection, graft failure, and death
The OPTN queries programs for information on acute rejection according to periods covered by specific reporting forms (0 to 6 months, 7 to 12 months, then annual periods), but dates of acute "Other race" includes Asian, Native American, Pacific Islander, and multi-racial. P-values: *P < .05-.002. **P = .001-.000. ***P < .0001, for differences of distributions of clinical traits among patients in a given diabetes treatment group compared with insulin-based reference.
TA B L E 1 (Continued) rejection within reporting periods are not collected. We defined acute rejection from SRTR records according to program reports that a treated acute rejection event occurred in a reporting period, as per prior methods for identifying acute rejection from U.S. registry data. 23, 24 Patient death was defined as death from any cause. We examined cause-specific death related to infections, malignancy, cardiovascular/cerebrovascular, and other causes in a secondary analysis. Graft failure was defined as return to maintenance dialysis or "preemptive" re-transplant. To assess the implications of diabetes treatment in the first year post-transplant, we examined clinical outcomes from >1 to 2 years post-transplant.
| Statistical analyses
Pharmacy claims and transplant recipient registry datasets were prepared in SAS 9.4 (SAS Institute, Cary, NC) and ana- 
| D ISCUSS I ON
By linking national transplant registry data with pharmacy claims data, we identified, characterized, and studied outcomes associated with anti-glycemic medication use in the first year after kidney transplant in a large, national, contemporary cohort with pre-existing diabetes mellitus. Use of diabetes regimens including metformin was uncommon (4.7%) and inversely correlated with eGFR. Metformin use was not associated with any adverse patient or graft outcomes. In fact, despite prior concerns for safety, metformin-based regimens were associated with 59% lower mortality compared to insulin use without metformin. There were also nonsignificant trends toward lower risk of acute rejection and all-cause graft failure among patients managed with metformin compared to those who received insulin without metformin. Notably, this survival difference did not occur with other oral hypoglycemic-based regimens excluding metformin (glitazone-based, sulfonylurea-based, or other), consistent with reports in the general population. 3 Associations of metformin with study outcomes were similar when compared to any nonmetformin treatment regimen.
Our work extends and confirms a prior analysis by Stephen et al 9 examining pharmacy fill records in patients who underwent F I G U R E 3 Acute rejection, graft failure, and death after the first transplant anniversary, according to diabetes treatment in first year post-transplant. P-values: *P < .05 for differences in >1 to 2 y outcomes for those in a given diabetes treatment group compared with insulinbased reference . KTx, kidney transplant. Yrs, years transplant before recent changes in guidelines for metformin prescribing in CKD. 25 The evolution in metformin guidelines motivated our study to include more recent data, which supports the need for continued study over time. Differences in our current study compared with the work of Stephen et al include our examination of a broader spectrum of outcomes including rejection and cause-specific death, categorization of patients who did not receive metformin into a variety of regimens, and focus on patients with established type 2 diabetes mellitus prior to transplant, whereas Stephen et al included those with both pretransplant diabetes mellitus and NODAT. We also analyzed metformin use with respect to GFR categories including in patients with eGFR < 30 mL/min per 1.73 m 2 , for whom metformin use is currently contraindicated by the U.S. Food and Drug Administration (FDA). 25 Importantly, primary inferences are consistent across both studies despite different samples and data sources.
The main anti-glycemic effect of metformin is inhibiting mitochondrial glycerophosphate dehydrogenase (mGPD), a liver enzyme involved in gluconeogenesis, 26 and enhancing insulin-mediated glucose utilization in peripheral tissues. 27 Metformin has been associated with lower all-cause mortality compared with insulin and other oral hypoglycemic agents in the general population. 3 In an observational study using a United Kingdom database of 78 241 patients treated with metformin, 12 222 matched patients with sulfonylurea, and 90 463 matched subjects without diabetes mellitus, metformin users were noted to have lower mortality compared with diabetic patients using sulfonylureas and with nondiabetic controls. 28 Metformin affects various cellular pathways associated with anti-aging, including inflammation, cell survival, autophagy, stress defense, and protein synthesis. 29 Observed survival benefits have been attributed to several reasons. Obesity is a risk factor for death, 30 and unlike insulin and sulfonylureas, which are associated with weight gain, metformin is associated with weight reduction.
31
Dyslipidemia is also a well-known risk factor for mortality, especially cardiovascular death. 32 Metformin improves the lipid profile F I G U R E 4 Adjusted associations of diabetes treatment in first year post-transplant with subsequent acute rejection, graft failure and death. Adjusted for recipient, donor, and transplant clinical factors as listed in Table 1 . ACGF, allcause graft failure; DCGF, death-censored graft failure; KTx, kidney transplant. *P < 0.05 by reducing serum low-density lipoprotein cholesterol concentrations and increasing serum high-density lipoprotein cholesterol concentrations. 33 Metformin has also been associated with lower risk of cancer and reduction in cancer mortality in diabetic patients, 34 an effect that may be mediated by regulation of AMP (adenosine monophosphate)-activated protein kinase (AMPK) through the tumor-suppressor liver kinase B1. 35 Metformin is also known to have direct anti-inflammatory effects. 36 The most common side effects associated with metformin are gastrointestinal (eg, nausea, abdominal cramps, and diarrhea). 33 Less commonly, metformin has been associated with vitamin B12 deficiency and peripheral neuropathy. 37 The most concerning, albeit rare, side effect of metformin is lactic acidosis, which can be fatal. 38 We hypothesized that due to safety concerns, the use of metformin in the kidney transplant population would be low. The observed frequency of 4.7% is substantially lower than use among patients with type 2 diabetes mellitus in the general population and is consistent with prior studies of transplant recipients. 9 Often GFR in transplant recipients is <60 mL/min/1.73 m 2 , a level associated with the diagnosis of CKD especially when recipient and donor age is >60 years. 44 Not surprisingly, we observed graded declines in metformin use with lower levels of renal function and among recipients of expanded criteria donor kidneys. Moreover, as many type 2 diabetic patients with kidney failure require insulin before transplant, providers might be reluctant to change anti-glycemic therapies after transplant, particularly with the combined impact of higher insulin clearance from improved GFR and the hyperglycemic stresses of immunosuppression. Notably, there was a trend toward more metformin use in more recent years of the study, reflecting the general practices of more common metformin use in patients with mild/moderate kidney disease in recent times based on newer safety data. 25 Although our data did not include information on lactic acidosis, we examined mortality as a key safety measure. Metformin was not associated with increased risk of any cause of death, but rather was associated with significantly lower all-cause, malignancy-related, infection-related, and "other" deaths, and with trends toward lower risks of unknown and cardiovascular death. While the potential mechanisms of cancer death are noted earlier, the reduction in infection-related death is an interesting finding. It is possible that the anti-inflammatory properties of metformin, 36 along with its ability to activate AMPK, a protein that is also involved in the pathogenesis of viral infections, 45 play a role. The trends toward reduced cardiovascular death may be a manifestation of the purported benefits on cardiovascular risk noted above, but given the lack of statistical significance, defining impact of this outcome in diabetic transplant recipients requires further study.
Regarding graft outcomes, we observed trends toward lower risk of graft failure and acute rejection with metformin-based regimens, but these patterns were not statistically significant in adjusted analyses. Potential mechanisms of allograft protection would include the ability of metformin to reduce kidney injury, possibly through AMPK activation 46, 47 and its anti-inflammatory and immune modulatory effects (eg, via AMPK-mTOR-STAT3 signaling 48 and T-cell regulation). 49 Again, our study does not support definitive conclusions for effects on allograft health, but the absence of increased risk is reassuring for the overall safety profile.
In the general population, metformin is usually titrated to the maximally effective dose of 2000 to 2500 mg/d. In our study, we noted that most (>50%) patients on metformin received a lower dose (average <650 mg/d). This pattern occurred even when the GFR was >60 mL/ min, when metformin dose reduction is not recommended and might reflect the practice of transplant providers to start and maintain lower doses in this population. Interestingly, in our analysis, 1.5% of diabetic transplant recipients with GFR <30 mL/min per 1.73 m 2 were exposed to metformin in the first year post-transplant, a significant portion of these to high doses (≥1500 mg/d) ( Figure 2 ). Further study is warranted to determine optimal dosing of metformin in transplant recipients to maximize benefits and reduce risks of those treated with this agent.
Limitations of our study include our inability to compare metformin monotherapy with other monotherapies, primarily due to the small number patients receiving such regimens. Notably, other oral hypoglycemic medication groups (exclusive of metformin) were not associated with any effects on mortality compared with the insulinbased reference group. In a systemic review of 179 trials and 25 observational studies, metformin-based combination therapy had effects similar to those of metformin monotherapy. 50 We also could not stratify our analysis of mortality based on GFR subgroups of metformin dose, again due to the low number of metformin-treated patients. Future work should examine whether the mortality benefit of metformin persists in patients on higher doses and with lower GFRs.
Although we adjusted for observed recipient, donor, and transplant factors, including the use of the propensity model to limit bias of "confounding by indication," the retrospective design poses inherent risk for residual confounding. It is noted that the metformin group was more likely to be female and have higher discharge/one-year eGFR;
and less likely to have received expanded criteria allografts. Hence, it is possible that despite measures to reduce confounding and bias, the mortality benefit in the metformin group was at least partially related to better overall health status. Findings may not be generalizable to patients who were not included in the linked databases. Further, we lacked laboratory values (eg, hemoglobin A1c, glucose levels) to adjust for level of glycemic control, and the metformin-treated patients may have had less severe diabetes mellitus. We also lacked granular measures of clinical complications such as lactic acidosis; however, we examined mortality and graft outcomes as safety measures.
These observational findings need to be validated in studies using a longer exposure, ideally with prospective designs to minimize confounding. A pilot protocol for a randomized clinical trial (Transdiab), with a 12-month follow-up, designed to study the feasibility, safety, and efficacy of metformin in NODAT, was recently published. 51 In conclusion, we found that in a national cohort of diabetic kidney transplant recipients, use of metformin-based diabetes therapy was uncommon, declined with lower levels of allograft function, and was not associated with increased risk of adverse patient or graft outcomes. Rather, metformin exposure was associated with reduced mortality and nonsignificant trends toward lower rates of rejection and graft loss. While these findings warrant replication in additional studies, examination of linked national registry and pharmacy fill records is an efficient strategy for identifying uncommon treatments in transplant recipients that can confirm, extend, and provide hypotheses for gold standard, but costly, clinical trials.
